Cited 118 times in
Perforation in colorectal stenting: a meta-analysis and a search for risk factors.
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 천재희 | - |
dc.date.accessioned | 2015-12-28T10:57:07Z | - |
dc.date.available | 2015-12-28T10:57:07Z | - |
dc.date.issued | 2014 | - |
dc.identifier.issn | 0016-5107 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/138376 | - |
dc.description.abstract | BACKGROUND: Recent studies suggest that there is a substantial risk of perforation after colorectal stent placement. OBJECTIVE: To identify risk factors for perforation from colonic stenting. DESIGN: A meta-analysis of 86 studies published between 2005 and 2011. SETTING: Multicenter review. PATIENTS: All patients who underwent colorectal stent placement. INTERVENTION: Colorectal stent placement. MAIN OUTCOME MEASUREMENTS: The occurrence of perforation with subgroup analyses for stent design, stricture etiology, stricture dilation, and concomitant chemotherapy, including the use of bevacizumab. RESULTS: A total of 4086 patients underwent colorectal stent placement; perforation occurred in 207. Meta-analysis revealed an overall perforation rate of 7.4%. Of the 9 most frequently used stent types, the WallFlex, the Comvi, and the Niti-S D-type had a higher perforation rate (>10%). A lower perforation rate (<5%) was found for the Hanarostent and the Niti-S covered stent. Stenting benign strictures was associated with a significantly increased perforation rate of 18.4% compared with 7.5% for malignant strictures. Dilation did not increase the risk of perforation: 8.5% versus 8.5% without dilation. The subgroup of post-stent placement dilation had a significantly increased perforation risk of 20.4%. With a perforation rate of 12.5%, bevacizumab-based therapy was identified as a risk factor for perforation, whereas the risk for chemotherapy without bevacizumab was 7.0% and not increased compared with the group without concomitant therapies during stent therapy (9.0%). LIMITATIONS: Heterogeneity; a considerable proportion of data is unavailable for subgroup analysis. CONCLUSIONS: The perforation rate of colonic stenting is 7.4%. Stent design, benign etiology, and bevacizumab were identified as risk factors for perforation. Intraprocedural stricture dilation and concomitant chemotherapy were not associated with an increased risk of perforation. | - |
dc.description.statementOfResponsibility | open | - |
dc.format.extent | 970~982 | - |
dc.relation.isPartOf | GASTROINTESTINAL ENDOSCOPY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Colon/injuries* | - |
dc.subject.MESH | Colonic Diseases/surgery* | - |
dc.subject.MESH | Global Health | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Incidence | - |
dc.subject.MESH | Intestinal Obstruction/surgery* | - |
dc.subject.MESH | Intestinal Perforation*/diagnosis | - |
dc.subject.MESH | Intestinal Perforation*/epidemiology | - |
dc.subject.MESH | Intestinal Perforation*/etiology | - |
dc.subject.MESH | Intraoperative Complications* | - |
dc.subject.MESH | Risk Assessment/methods* | - |
dc.subject.MESH | Risk Factors | - |
dc.subject.MESH | Stents/adverse effects* | - |
dc.title | Perforation in colorectal stenting: a meta-analysis and a search for risk factors. | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학) | - |
dc.contributor.googleauthor | Emo E. van Halsema | - |
dc.contributor.googleauthor | Jeanin E. van Hooft | - |
dc.contributor.googleauthor | Aaron J. Small | - |
dc.contributor.googleauthor | Todd H. Baron | - |
dc.contributor.googleauthor | Jesús García-Cano | - |
dc.contributor.googleauthor | Jae Hee Cheon | - |
dc.contributor.googleauthor | Moon Sung Lee | - |
dc.contributor.googleauthor | Se Hwan Kwon | - |
dc.contributor.googleauthor | Stéphanie Mucci-Hennekinne | - |
dc.contributor.googleauthor | Paul Fockens | - |
dc.contributor.googleauthor | Marcel G.W. Dijkgraaf | - |
dc.contributor.googleauthor | Alessandro Repici | - |
dc.identifier.doi | 10.1016/j.gie.2013.11.038 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A04030 | - |
dc.relation.journalcode | J00920 | - |
dc.identifier.eissn | 1097-6779 | - |
dc.identifier.pmid | 24650852 | - |
dc.identifier.url | http://www.sciencedirect.com/science/article/pii/S0016510713026345 | - |
dc.contributor.alternativeName | Cheon, Jae Hee | - |
dc.contributor.affiliatedAuthor | Cheon, Jae Hee | - |
dc.rights.accessRights | free | - |
dc.citation.volume | 79 | - |
dc.citation.number | 6 | - |
dc.citation.startPage | 970 | - |
dc.citation.endPage | 982 | - |
dc.identifier.bibliographicCitation | GASTROINTESTINAL ENDOSCOPY, Vol.79(6) : 970-982, 2014 | - |
dc.identifier.rimsid | 49135 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.